Anbio Biotechnology (NNNN): key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025): $8.6M
Net Income/Loss (FY2025): $6.4M
Total Assets (FY2025): $30.2M
Total Equity (FY2025): $30.2M
Cash Flows from Operating Activities (FY2025): -$6.7M

Source: Anbio Biotechnology 20-F filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.

Anbio Biotechnology (NNNN) Financials | Hub-Equity